Adlai Nortye Partners with ASK Pharm on Promising Cancer Drug for China Market
Adlai Nortye licenses AN9025, an experimental pan-RAS cancer drug, to ASK Pharm for development in Greater China in a deal worth up to $230 million.
/ 907 items
#Healthcare↓
Piper Sandler Backs Palisade Bio Ahead of Key Crohn’s Data
Piper Sandler starts coverage on Palisade Bio with an Overweight rating and a $25 target, citing strong potential for its Crohn’s disease drug PALI-2108.
BTIG Cuts Organogenesis Confidence on CMS Policy Delay
BTIG maintains $9 price target on Organogenesis but reduces 2026 confidence after CMS delays skin substitute coverage rules, creating regulatory uncertainty for the wound care company.
Can-Fite Secures Brazilian Patent for Sexual Dysfunction Treatment
Can-Fite BioPharma receives Brazilian patent protection for its A3 adenosine receptor agonist drug targeting sexual dysfunction, expanding its presence in Latin America's pharmaceutical market.
H.C. Wainwright Starts Coverage on Inhibikase Therapeutics With Buy Rating
H.C. Wainwright begins coverage of Inhibikase Therapeutics with a Buy rating and $8 target, citing strong prospects for its Phase 3 PAH drug IKT-001.
Biohaven's Depression Drug BHV-7000 Falls Short in Clinical Trial
Biohaven's (BHVN) experimental depression treatment BHV-7000 didn't meet its primary goal in Phase 2 testing, though some patient subgroups showed promising trends.